Cost Is the Hidden Barrier to Biologic Adherence

You've done the clinical work. You've diagnosed the condition, tried first-line therapies, and determined that a TNF blocker is the right next step for your patient. You prescribe Hadlima (Adalimumab-bwwd) — a biosimilar to Humira that's already significantly less expensive at the wholesale level. Then your patient calls the office: they can't afford it.

This scenario plays out daily in rheumatology, gastroenterology, and dermatology practices across the country. Even with Hadlima's lower price point, biologic medications remain a major financial burden for many patients. And cost-driven non-adherence leads to disease progression, emergency visits, hospitalizations, and ultimately higher costs for everyone.

This guide is designed to help prescribers and their care teams navigate the savings landscape for Hadlima so you can keep your patients on therapy and out of the emergency department.

What Your Patients Are Actually Paying

Understanding the cost landscape helps frame the conversation:

• Hadlima WAC (wholesale acquisition cost): Approximately $1,038 per carton (one 40 mg dose)
• Humira WAC: Approximately $6,922 per carton
• Cash price without insurance: Roughly $1,000–$1,500 per injection for Hadlima at retail pharmacies

While Hadlima represents an approximately 85% savings over Humira at the wholesale level, the out-of-pocket cost for patients depends heavily on their insurance structure:

• Commercial insurance with specialty tier: Copays can range from $50 to $500+ per fill, depending on the plan's specialty drug tier and coinsurance structure.
• Medicare Part D: Patients in the coverage gap ("donut hole") may face significant out-of-pocket costs, though biosimilar coverage has been improving.
• High-deductible health plans: Patients may owe the full negotiated price until they meet their deductible — potentially $1,000+ for a single fill.
• Uninsured patients: Face the full cash price unless they qualify for patient assistance programs.

The bottom line: even a "cheaper" biologic can be unaffordable without intervention.

Manufacturer Savings Programs

Organon $0 Co-Pay Savings Card

Organon offers a co-pay savings card that can reduce commercially insured patients' out-of-pocket cost to $0. Key details:

• Eligibility: Commercially insured patients with a valid Hadlima prescription
• Not eligible: Patients with government insurance (Medicare, Medicaid, Tricare, VA) due to federal anti-kickback regulations
• How to enroll: Patients can enroll through Organon's website or your office can help initiate the process
• Annual maximums: Most manufacturer co-pay programs have an annual cap — verify current terms with Organon

For your commercially insured patients, this should be the first option you present. It's the simplest path to $0 out-of-pocket cost and takes minutes to set up.

Organon Assist Patient Assistance Program

For uninsured or underinsured patients who meet income eligibility criteria, Organon's patient assistance program may provide Hadlima at no cost. This is a critical resource for your most financially vulnerable patients.

• Eligibility: Typically based on household income (often at or below 400% of the federal poverty level)
• Application: Requires a completed application form, proof of income, and a valid prescription
• Processing time: Allow 2–4 weeks for approval — plan ahead so patients don't have a gap in therapy

Your office staff can download applications from Organon's website or find them through databases like NeedyMeds (needymeds.org) and RxAssist (rxassist.org).

Coupon and Discount Cards

Beyond manufacturer programs, third-party discount cards can help patients who fall through the cracks — particularly those who are commercially insured but don't qualify for the manufacturer co-pay card, or who are between coverage:

• GoodRx — Shows cash prices at nearby pharmacies and may offer coupons for Hadlima
• SingleCare — Free prescription savings card accepted at most major pharmacies
• RxSaver — Compares prices and provides printable coupons
• BuzzRx — Another free discount card option

Note that discount cards are typically most useful for cash-paying patients and usually can't be combined with insurance. For insured patients, the manufacturer co-pay card is almost always a better deal.

For a comprehensive list of savings options your patients can explore on their own, direct them to our patient savings guide for Hadlima.

Generic Alternatives and Therapeutic Substitution

There is no traditional generic for Hadlima — it is itself a biosimilar to Humira (Adalimumab). However, the adalimumab biosimilar landscape gives you meaningful options for therapeutic substitution:

Available Adalimumab Biosimilars

• Amjevita (Adalimumab-atto) by Amgen
• Hyrimoz (Adalimumab-adaz) by Sandoz
• Cyltezo (Adalimumab-adbm) by Boehringer Ingelheim — notably, Cyltezo is designated as interchangeable, meaning pharmacists can substitute it without prescriber approval in many states

When evaluating biosimilar options for cost purposes, consider:

• Formulary placement: Which biosimilar does your patient's insurance plan prefer? A non-preferred biosimilar may actually cost the patient more, even if its WAC is lower.
• Savings program availability: Each manufacturer offers its own co-pay program. Check which provides the best patient assistance for your specific patient's situation.
• Availability: Not all biosimilars are stocked at all pharmacies. Use Medfinder for Providers to check availability and help your patients locate their medication.

When to Consider Therapeutic Class Alternatives

If cost remains prohibitive even with biosimilar options and savings programs, consider whether a different drug class might be clinically appropriate:

• JAK inhibitors (Rinvoq, Xeljanz) — Oral medications that may have different formulary placement
• IL-17 inhibitors (Cosentyx, Taltz) — For psoriasis and psoriatic arthritis
• IL-23 inhibitors (Skyrizi, Tremfya) — For psoriasis with potentially less frequent dosing
• Conventional DMARDs — Methotrexate, Leflunomide, and Sulfasalazine are dramatically less expensive, though not equivalent in efficacy for all patients

Therapeutic substitution should always be a clinical decision, not purely a financial one — but cost reality is part of the clinical picture when non-adherence is the alternative.

Building Cost Conversations into Your Workflow

Many providers are uncomfortable discussing medication costs, but proactive cost conversations improve adherence and outcomes. Here's how to systematize it:

At the Point of Prescribing

• Ask about coverage: "Before I send this prescription, let's make sure we know what your insurance covers and what your out-of-pocket cost will look like."
• Mention savings upfront: "Hadlima has a $0 co-pay card for most commercially insured patients. My staff will get you enrolled before you leave today."
• Set expectations: "The prior authorization process usually takes 1–3 weeks. We'll handle the paperwork, but let us know if you don't hear from the pharmacy within two weeks."

Train Your Staff

Your medical assistants, nurses, and front-desk staff are often the first to hear about cost barriers. Equip them with:

• A quick reference sheet for manufacturer savings programs (Organon $0 co-pay card enrollment, Organon Assist application)
• Links to NeedyMeds and RxAssist for patient assistance lookups
• A process for checking formulary status before submitting prescriptions
• Scripts for discussing costs without judgment: "Many patients need help with medication costs — let me walk you through some options."

At Follow-Up Visits

• Check adherence: If a patient is missing doses, cost is often the reason. Ask directly.
• Reassess savings programs: Insurance plans change annually. A patient who was covered last year may need a new savings strategy this year.
• Document everything: Note the patient's cost barriers and the programs you've explored in their chart. This is especially important for prior authorization appeals.

Leverage Your Specialty Pharmacy Relationships

Specialty pharmacies often have financial counselors on staff who can help patients navigate coverage and savings programs. Building a relationship with your preferred specialty pharmacy means your patients have an additional safety net when cost issues arise.

Final Thoughts

The clinical value of Hadlima is clear — it's a well-established TNF blocker with a strong efficacy profile across multiple autoimmune conditions, and its biosimilar pricing makes it one of the most cost-effective options in the adalimumab class. But even a "cheaper" biologic is expensive by any normal standard, and your patients need help navigating the financial side of their treatment.

By integrating cost conversations into your workflow, training your staff on available programs, and staying current on formulary placement and savings options, you can remove one of the biggest barriers to biologic adherence. Your patients will be healthier for it, and your practice will see fewer disease flares and emergency interventions.

For real-time pharmacy availability and provider tools, visit Medfinder for Providers.